Perguntar
Consultar
Descobrir
Calcular
Cadastre-se
Cadastre-se
Entrar
Entrar
Descobrir
FDA Approves REMS Modification for FILSPARI® (sparsentan) in Adults with IgA Nephropathy: Reduced Liver Monitoring and Removal of Embryo-Fetal Toxicity REMS Requirement - Notícias Vera Health